What influences acceptability of long-acting injectable ART and treatment setting: preliminary qualitative findings from the ILANA study

Hayes, Rosalie*; Mwendera Chikondi*; Apea, Vanessa¹; Paparini, Sara¹; Orkin, Chloe*¹
¹ SHARE Collaborative, Queen Mary University of London, London, UK; ²University of Liverpool, Liverpool, UK; *Joint first and last authors

Background

- ILANA (Implementing Long-Acting Novel Antiretrovirals) is a pragmatic implementation study about feasibility and acceptability of long-acting Cabotegravir and Rilpivirine (CAB + RPV LA) administration at NHS HIV clinics and community settings for people with HIV.
- As an anti-agiest, anti-sexist and anti-racist trial, ILANA capped recruitment to ensure representation of:
  - 50% women
  - 50% people from racially minoritised communities
  - 30% people aged 50+.
- Fourteen patients and 13 HCPs were interviewed.

Methods

- Semi-structured qualitative interviews (Aug-Nov 2022) with patients and health care professionals (HCPs) participating in ILANA.
- Purposive recruitment from six HIV clinics across Brighton, Liverpool, and London. Most interviews took place prior to first injection.
- Thematic analysis performed on this ‘baseline’ dataset.
- Follow up interviews planned for August 2023.

Findings

Patient characteristics
- Fourteen patients and 13 HCPs were interviewed.
- Patient participants were 57% female, 57% from racially minoritised groups, and the median age was 49 (IQR 40-54).
- HCPs included doctors, nurses, and pharmacists.

Barriers

- **Relief from pill fatigue**
  - Nearly all participants highlighted the substantial mental health improvement experienced by patients due to the relief from taking daily medication that CAB + RPV LA provides.

- **Discreet nature of injections**
  - For patients who did not want others to know about their medication use, CAB + RPV LA offers discretion and privacy, providing further stress relief.

- **Convenience of injection schedule**
  - Most patients were confident they could manage appointments within their schedules. Most did not perceive the injection appointment schedule as onerous, seeing it as a lesser burden than daily pill-taking.

- **Benefits outweigh discomfort**
  - Some patients expressed concerns about injection pain, but most felt this was outweighed by the treatment’s benefits, in particular improved mental health due to reduced medication burden.

- **Confidence in effectiveness of CAB + RPV LA**
  - Participants were largely confident in CAB + RPV LA’s effectiveness at suppressing HIV viral load. Patients attributed this to conversations with trusted clinical staff. Although both HCPs and patient participants expressed nervousness prior to first injection, their confidence grew after receiving the first viral load results.

- **Trust in clinical staff**
  - Most patients at this initial stage preferred to receive injections at their clinic rather than a community setting. They cited supportive relationships with clinical staff as a key factor, built upon trust and confidentiality, often over many years.

- **Side-effects**
  - Many patient participants cited side-effects as a reason they would stop CAB + RPV LA, although none had experienced at the time of interview. They appreciated that the oral lead-in medication would allow them to stop treatment quickly if they experienced side-effects.

- **Potential for drug resistance**
  - Although most participants were positive about the long-term benefits of LA-ART, some were concerned about the potential for drug resistance in the event of treatment failure.

- **Restrictive eligibility criteria**
  - Some HCPs were concerned that the current eligibility criteria for LA-ART would exclude patients who might benefit most.

- **Stigma and confidentiality**
  - Those who preferred community settings cited proximity as their main advantage. However, several patients expressed concerns about HIV stigma and confidentiality breaches in non-HIV-specialist settings.

Facilitators

- **For so many decades, I’ve been having tablets day in and day out, and now I have two monthly treatment... It’s a joy for me**
  - Patient, 62 yrs, Black African, Male

- **[At] the first visit, they have been quite anxious about having the injections... But once they’ve got the result of the first viral load back, they seem to be a bit more settled with the process.”**
  - HCP, Doctor, Brighton

- **Just facing new people, you know, and having to go through everything you’ve been through and yet at [HIV clinic], they know me in and out, you know what I mean.”**
  - Patient, 54 years, Black African, female

- **Well, the big challenge is to be honest, what will be the side effects, because it is new, I don’t know.”**
  - Patient, 42 years, Asian Other, Female

Discussion

- **“The people that seem to really need the injectables are the ones that don’t fulfil the eligibility criteria. And that’s my greatest frustration.”**
  - HCP, Nurse, Liverpool

- **CAB + RPV LA is highly acceptable** to patients and HCPs.
- **General preference for clinical treatment setting among patients, highlights importance of enabling choice.**
- **Limitations include patients already participating in ILANA and prospective nature of study.**
- Further research needed to understand if participants’ experience matches their expectations.

Acknowledgements

Many thanks to the participants, staff at participating NHS trusts, Nishat Halim, Sadna Ullah, Bakita Kasadha, and the SHARE Community Advisory Board. ILANA is funded by ViiV Healthcare.

BHIVA 2023 Spring Conference, 24-26 April, Gateshead, UK

Corresponding author: Rosalie Hayes, rhayes@qmul.ac.uk